Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia (NVDA) technology to either enhance their products or assist in the development of new treatments, the chipmaker’s CEO said on Tuesday.
Speaking at the Nvidia (NVDA) GTC conference in Washington, Jensen Huang said that J&J has been using Nvidia products to help train some of its surgical robots and simulating procedures with “digital twins.”
“These Johnson & Johnson surgical robots are even going to perform noninvasive surgery at a precision the world has never seen before,” the exec said.
Huang also referenced a new partnership with Eli Lilly to build a new supercomputer that will act as an “AI factory” to discover new medicines as well as improve the manufacturing of drugs.
“By embedding intelligence into every layer of our workflows, we’re opening the door to a new kind of enterprise: one that learns, adapts and improves with every data point,” Lilly SVP and Chief AI Officer Thomas Fuchs said in a statement. This isn’t just about speed, but rather interrogating biology at scale, deepening our understanding of disease and translating that knowledge into meaningful advances for people…”
The supercomputer will be the first Blackwell-Based Nvidia DGX SuperPOD with DGX B300 systems, powered by over 1,000 B300 GPUs.